SSY Group (HKG:2005) said its Morinidazole has received registration approval from China's National Medical Products Administration as a bulk drug for preparations already on the market, according to a Tuesday Hong Kong bourse filing.

Morinidazole, a nitroimidazole antibiotic, is mainly used to treat appendicitis and pelvic inflammatory disease caused by anaerobic bacteria, the company said.